Journals / Türk Oftalmoloji Dergisi / 2011 / Cilt: 41 - Sayı: 1

Tip 2 idiopatik parafoveal telenjektazili bir olguda bevacizumab ile triamsinolon asetonidin karşılaştırılması

Comparison between efficacy of triamcinolone acetonide and bevacizumab in a case with type 2A idiopathic parafoveal telangiectasia

Pages
6–9
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The efficacy and permanence of influence-duration of action of triamcinolone acetonide and bevacizumab were similar in our case.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the efficacy of intravitreal triamcinolone acetonide and bevacizumab in the treatment of a case of type 2A idiopathic parafoveal telangiectasia (IPT).
📊
Key Findings & Data:Material and Method: A 55-year-old man with complaint of decreased vision in both eyes was diagnosed as type 2A IPT after a complete ophthalmological examination, fundus fluorescein angiography (FA) and optical coherence tomography (OCT).
💡
Conclusion & Impact:The efficacy and permanence of influence-duration of action of triamcinolone acetonide and bevacizumab were similar in our case.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the efficacy of intravitreal triamcinolone acetonide and bevacizumab in the treatment of a case of type 2A idiopathic parafoveal telangiectasia (IPT). Material and Method: A 55-year-old man with complaint of decreased vision in both eyes was diagnosed as type 2A IPT after a complete ophthalmological examination, fundus fluorescein angiography (FA) and optical coherence tomography (OCT). We injected intravitreally 4 mg /0.1 cc of triamcinolone acetonide into the right eye and 24 hours later 1.25 mg /0.05 cc of bevacizumab into the left eye. The patient was evaluated on the first day, first week, first month, and the third month with FA and OCT.Results: Before treatment, best-corrected visual acuity (BCVA) was 5/100 in the right eye and 5/10 in the left eye. At the first-week post-treatment visit, BCVA improved to 5/10 in the right eye and 10/10 in the left eye. On FA, edema in the temporal foveal area was detected in both eyes. This macular edema began to decrease at the first-week visit. Visual acuity was the same on the first- and third-month visits. The FA findings also remained the same. During this 3-month follow-up period, the patient did not need any other additional treatment. Discussion: Intravitreal injections of triamcinolone acetonide and bevacizumab are optional modalities in the treatment of type 2 IPT. The efficacy and permanence of influence-duration of action of triamcinolone acetonide and bevacizumab were similar in our case.

Özet

Amaç: Tip 2 İdiopatik Parafoveal Telenjektazili (İPT) bir olgunun tedavisinde intravitreal bevacizumab ile triamsinolon asetonidin etkinliğinin karşılaştırılması. Gereç ve Yöntem: Elli beş yaşındaki erkek hasta, her iki gözde görme azalması şikayeti ile kliniğimize başvurdu. Ayrıntılı oftalmolojik muayene, fundus flöresein anjiografi (FFA) ve optik koherans tomografi (OKT) sonuçlarına dayanarak hastaya Tip 2A İPT tanısı kondu. Tedavi olarak hastanın sağ gözüne intravitreal 4 mg/0,1 cc triamsinolon asetonit, sol gözüne ise 24 saat sonra 1,25 mg / 0,05 cc intravitreal bevacizumab uygulandı. Hasta enjeksiyonlardan sonra 1. gün, 1. hafta, 1. ay ve 3.ay sonunda FFA ve OKT ile değerlendirildi. Sonuçlar: Tedavi öncesi hastanın en iyi düzeltilmiş görme keskinliği sağ gözde 5/100, sol gözde ise 5/10 idi. Tedavi sonrası birinci haftada hastanın sağ görmesi 5/10, solda ise 10/10 ulaştı. FFA' da her iki gözde fovea temporalinde ödem tespit edildi. Bu makular ödem tedaviden 1 hafta sonra azalmaya başladı. Görme keskinliği 1. ay ve 3. ay sonunda aynı seviyede kaldı. FFA bulguları da aynı şekilde sebat etti. Bu 3 aylık süresi boyunca hastaya ek tedavi yapılması gerekmedi. Tartışma: İntravitreal triamsinolon asetonit ve bevacizumab Tip 2 İPT tedavisinde alternatif seçeneklerdir. Bu olguda hem triamsinolon asetonit hem bevacizumab'ın etkili olduğunu, etkinliklerinin ve etkinlik sürelerinin benzer olduğunu gösterdik.

🔖

Cite This Article

ÖZKAN, B., TOKLU, Y., ŞİMŞEK, Ş., ANAYOL, M. A., ALTINTAŞ, A. K., RAZA, S. (2022). Tip 2 idiopatik parafoveal telenjektazili bir olguda bevacizumab ile triamsinolon asetonidin karşılaştırılması. Türk Oftalmoloji Dergisi, Cilt: 41 - Sayı: 1, 6–9. https://ajindex.com/articles/638386

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Arevalo JF, Sanchez JG, Garcia RA et al. Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2007;245:1673-80. [Abstract] 2. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100:1536-46. [Abstract] 3. Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology. 2007;114:1736-42. [Abstract] 4. Millay RH, Klein ML, Handelman IL, Watzke RC. Abnormal glucose metabolism and parafoveal telangiectasia. Am J Ophthalmol. 1986 15;102:363-70. [Abstract] 5. Paunescu LA, Ko TH, Duker JS, Chan A, Drexler W, Schuman JS, Fujimoto JG. Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006;113:48-57. [Abstract] 6. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-705. [Abstract] 7. Charbel Issa P, Holz FG, Scholl HP. Intravitreal bevacizumab for the treatment of type 2 idiopathic macular telengiectasis. Retin Cases Brief Rep. In pres. 8. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124:450-60. [Abstract] 9. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of juxtafoveal telangiectasis. Retina. 2003;23:113-6. 10. Cakir M, Kapran Z, Basar D, Utine CA, Eroglu F, Perente I. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol. 2006;16:711-7. [Abstract] 11. Green WR, Quigley HA, De la Cruz Z, Cohen B. Parafoveal retinal telangiectasis. Light and electron microscopy studies. Trans Ophthalmol Soc U K. 1980;100:162-70. [Abstract] 12. Sanchez JG, Garcia RA, Wu L et al. Optical coherence tomography characteristics of group 2A idiopathic parafoveal telangiectasis. Retina. 2007;27:1214-20. [Abstract] 13. Gupta V, Gupta A, Dogra MR, Agarwal A. Optical coherence tomography in group 2A idiopathic juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging. 2005;36:482-6. [Abstrac